Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer

被引：0
|
作者：
Ken-ichi Fujita
Yuichi Ando
Fumio Nagashima
Wataru Yamamoto
Hisashi Eodo
Kazuhiro Araki
Keiji Kodama
Toshimichi Miya
Masaru Narabayashi
Yasutsuna Sasaki
机构：
[1] Saitama Medical University,Department of Clinical Oncology
[2] Saitama Medical University,Project Research Laboratory, Research Center for Genomic Medicine, Saitama Medical Center
来源：
Cancer Chemotherapy and Pharmacology | 2007年 / 60卷
关键词：
Irinotecan; SN-38; Polymorphism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：515 / 522
页数：7
相关论文
共 50 条
  • [1] Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer
    Fujita, Ken-Ichi
    Ando, Yuichi
    Nagashima, Fumio
    Yamamoto, Wataru
    Eodo, Hisashi
    Araki, Kazuhiro
    Kodama, Keiji
    Miya, Toshimichi
    Narabayashi, Masaru
    Sasaki, Yasutsuna
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (04) : 515 - 522
  • [2] Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with low glucuronidase activity for irinotecan metabolite SN-38 in Japanese cancer patients
    Fujita, Ken-Ichi
    Ando, Yuichi
    Nagashima, Fumio
    Yamamoto, Wataru
    Endo, Hisashi
    Araki, Kazuhiro
    Kodama, Keiji
    Miya, Toshimichi
    Narabayashi, Masaru
    Sasaki, Yasutsuna
    CANCER RESEARCH, 2006, 66 (08)
  • [3] Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations
    Hiromichi Maeda
    Shoichi Hazama
    Abdiev Shavkat
    Ken Okamoto
    Koji Oba
    Junichi Sakamoto
    Kenichi Takahashi
    Masaki Oka
    Daisuke Nakamura
    Ryouichi Tsunedomi
    Naoko Okayama
    Hideyuki Mishima
    Michiya Kobayashi
    Molecular Diagnosis & Therapy, 2014, 18 : 333 - 342
  • [4] Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations
    Maeda, Hiromichi
    Hazama, Shoichi
    Shavkat, Abdiev
    Okamoto, Ken
    Oba, Koji
    Sakamoto, Junichi
    Takahashi, Kenichi
    Oka, Masaki
    Nakamura, Daisuke
    Tsunedomi, Ryouichi
    Okayama, Naoko
    Mishima, Hideyuki
    Kobayashi, Michiya
    MOLECULAR DIAGNOSIS & THERAPY, 2014, 18 (03) : 333 - 342
  • [5] Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
    Paoluzzi, L
    Singh, AS
    Price, DK
    Danesi, R
    Mathijssen, RHJ
    Verweij, J
    Figg, WD
    Sparreboom, A
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (08): : 854 - 860
  • [6] Linkage disequilibrium of UGT1A1*6 and UGT1A1*28 in relation to UGT1A6 and UGT1A7 polymorphisms
    Urawa, Naohito
    Kobayashi, Yoshinao
    Araki, Jun
    Sugimoto, Ryosuke
    Iwasa, Motoh
    Kaito, Masahiko
    Adachi, Yukihko
    ONCOLOGY REPORTS, 2006, 16 (04) : 801 - 806
  • [7] Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
    Singh, A
    Paoluzzi, L
    Price, D
    Danesi, R
    Mathijssen, RH
    Verweij, J
    Figg, WD
    Sparreboom, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 145S - 145S
  • [8] Inhibition of UGT1A1*1 and UGT1A1*6 catalyzed glucuronidation of SN-38 by silybins
    Li, Wei
    Chen, Yin-Nan
    Chen, Yue-Yue
    Wang, Zhe
    Wang, Zhen
    Jiang, Li-Li
    Shi, Hong-Can
    Liu, Yong
    CHEMICO-BIOLOGICAL INTERACTIONS, 2022, 368
  • [9] Haplotype analysis of UGT1A1 and UGT1A9 gene polymorphisms related to the glucuronidation of SN-38, the active metabolite of irinotecan.
    Liu, W
    Innocenti, F
    Chen, PX
    Desai, A
    Grimsley, C
    Di Rienzo, A
    Das, S
    Ratain, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 148S - 148S
  • [10] The influence of functional polymorphisms in UGT1A7 and UGT1A9 on irinotecan pharmacokinetics in Asian cancer patients.
    Rammohan, M
    Jeevananthinee, J
    Zhou, QY
    Tan, EH
    Sparreboom, A
    Verweij, J
    Balram, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 136S - 136S
12345